Comparative Pharmacology
Head-to-head clinical analysis: ARISTADA versus CAPLYTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTADA versus CAPLYTA.
ARISTADA vs CAPLYTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
None Documented
None Documented
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic